A series of cardiometabolic-related news items have been observed from Insulet, Senseonics, Akero Therapeutics, Skye Bioscience, MannKind, and Xeris. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Novo Nordisk, Tandem Diabetes Care, Zealand Pharma, Altimmune, NewAmsterdam Pharma, Esperion, Viatris, and DarioHealth. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: AstraZeneca initiated a Ph3 baxdrostat + dapagliflozin combination trial in HF (Prevent-HF; view CT.gov record); Ionis (press release; slides) and Teva Pharmaceuticals (press release) hosted their respective Q3 ’24 earnings calls. Below, FENIX provides highlights and insights for the respective news items.
Novo Nordisk hosted its Q3 ’24 earnings call (press release; slides) and provided updates across its CVRM portfolio, including new semaglutide PAD data. FENIX will cover Novo’s London Q3 ’24 earnings call tomorrow, November 7, 2024. Below, FENIX provides highlights and insights from the Q3 ’24 earnings call.
A series of cardiometabolic-related news items have been observed from: AstraZeneca, Novo Nordisk, Vertex, and One Health Biosensing. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Viking Therapeutics, Novo Nordisk, Skye Bioscience, Lexicon Pharmaceuticals, and NeuroBo Pharmaceuticals. FENIX will provide coverage for the AstraZeneca weight management investor event in tomorrow’s blast (view here). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Novo Nordisk, Abbott, Alnylam, and Regeneron. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Lexicon, Novo Nordisk, Amgen, Madrigal, Biomea Fusion, BI/Gubra, Inventiva, Teladoc, and Amarin. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from FDA/Novo Nordisk, Beta Bionics, Insulet, and Zealand Pharma. Below, FENIX provides highlights and insights for the respective news items.
Lilly hosted its Q3 ’24 earnings call (press release; slides) and provided updates across its CVRM portfolio. Of note, Lilly decreased its FY2024 revenue guidance by $600M to $45.4B- $46B, primarily due to the acquired IPR&D charges incurred in Q3 as well as investments in increasing the supply of tirzepatide. Following the updated guidance, Lilly’s stock price decreased by ~8%.